The Effect of Reiki in Patients With Type-II Diabetes
The Effect of Reiki on Subjective Well-being, Happiness, and Some Metabolic Variables in Patients With Type-II Diabetes: Single-blind Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Osmaniye, Turkey, 80000
- Yüce
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosed with Type-II Diabetes Mellitus at least 6 months prior
- Had a BMI ≥ 25kg/m² (overweight or obese)
- HbA1c ≥ 6.5%
Exclusion Criteria:
- Being diagnosed with another disease and needing treatment during the data collection process
- Being a Reiki practitioner or instructor
- Using insulin for treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Reiki
The Reiki group received 20 minutes of remote Reiki once a day for 4 consecutive days
|
The Reiki group received distant Reiki application to their energy centers for 20 minutes, once a day, for 4 consecutive days, by researchers with Reiki Stage II training under the guidance of a researcher with the Usui Reiki Master & Teacher degree.
|
|
No Intervention: Control
No intervention was applied to the control group
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Subjective Well-Being
Time Frame: 3 months
|
The Subjective Well-Being Scale is a measurement tool developed to determine the subjective experiences and vitality levels of individuals in terms of feeling lively, energetic and alert, and is based on individuals providing information about themselves.
The seven-item, 7-point Likert-type scale is ranked from 1 (Does not apply to me at all) to 7 (Completely applies to me), and participants are asked to determine the extent to which they agree with the statement in each item.
The scores of all items in the scale can be added to obtain the individual's total subjective vitality score.
The range of scores on the scale varies between 7 and 49.
High scores on the scale indicate that the individual has a high level of subjective vitality.It is expected that the scores that the participants receive from this scale will increase in the final measurement.
|
3 months
|
|
Happiness
Time Frame: 3 months
|
OXFORD Happiness scale is a 29-item, 6-point Likert-type scale (1-I completely disagree, 6-I completely agree) developed to measure happiness.
A high score obtained from the scale indicates an increase in the level of happiness.
The scale score range varies between 29-174.
It is expected that the scores that the participants receive from this scale will increase in the final measurement.
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
HbA1c (%)
Time Frame: 3 months
|
HbA1c, is the main biomarker used to assess long-term glycaemic control in individuals with diabetes.In the final test, this value was targeted to be below the level recorded in the pre test in Reiki gruop.
|
3 months
|
|
Fasting blood glucose level (mg/dL)
Time Frame: 3 months
|
Fasting blood glucose level is the level of glucose in the blood measured after at least 8 hours of overnight fasting.In the final test, this value was targeted to be below the level recorded in the pre test.
|
3 months
|
|
Postprandial blood glucose levels (mg/dl)
Time Frame: 3 months
|
Postprandial blood sugar is the blood sugar level measured 2 hours after food intake (first bite).
It should not be over 140 mg/dl.In the final test, this value was targeted to be below the level recorded in the first test.
|
3 months
|
|
Body mass index (kg/m2)
Time Frame: 3 months
|
The study initially included individuals who were overweight or obese (BMI ≥ 25kg/m²).
The aim was to reduce the body mass index of the participants in the Reiki group, measured in the post-test.
|
3 months
|
|
LDL-kolesterol (mg/dL)
Time Frame: 3 months
|
The highest LDL (low density lipoprotein) level in the post-test measurements of individuals in the Reiki group was targeted to be 130 mg/dL.
|
3 months
|
|
HDL-kolesterol (mg/dL)
Time Frame: 3 months
|
The lowest HDL (high density lipoprotein) level in the post-test measurements of individuals in the Reiki group was targeted to be 40 mg/dL for women and 50 mg/dL for men.
|
3 months
|
|
Total kolesterol (mg/dL)
Time Frame: 3 months
|
The highest total kolesterol level in the post-test measurements of individuals in the Reiki group was targeted to be 200 mg/dL.
|
3 months
|
|
Triglyceride levels (mg/dL)
Time Frame: 3 months
|
The highest triglyceride level in the post-test measurements of individuals in the Reiki group was targeted to be 150 mg/dL.
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2022/5/2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.